Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant.
ABSTRACT Background
Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant.
Aim
To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease.
Methods
Twenty-five women from the University of Calgary inflammatory bowel disease (IBD) pregnancy clinic on maintenance infliximab or adalimumab were recruited prospectively with serum bio-banking performed each trimester. Infliximab trough and adalimumab steady-state levels were the outcomes of interest and were analysed using the ANSER infliximab and adalimumab assays. Multivariate linear mixed-effects models were constructed to assess infliximab and adalimumab drug levels during pregnancy adjusting for the clinical covariates of albumin, BMI and CRP.
Results
Fifteen women (eight Crohn's disease, seven ulcerative colitis) received infliximab and 10 women with 11 pregnancies were treated with adalimumab. Median age was 29.6 years (IQR: 27.6-31.2 years). Median disease duration was 9.2 years (IQR: 3.16-15.0 years). Median trough infliximab concentrations were 8.50 lg/mL (IQR: 7.23-10.07 lg/mL), 10.31 lg/mL (IQR: 7.66-15.63 lg/mL) and 21.02 lg/mL (IQR: 16.01-26.70 lg/mL) at trimesters 1, 2 and 3 respectively. Significant changes in albumin and BMI (P < 0.05) but not CRP (P > 0.05) were documented throughout pregnancy. After adjusting for albumin, BMI and CRP, infliximab trough levels increased during pregnancy, by 4.2 lg/mL per trimester (P = 0.02), while adalimumab drug levels remained stable (P > 0.05).
BACKGROUND
Women with inflammatory bowel disease (IBD) are at increased risk of adverse materno-fetal outcomes especially in the setting of active disease. 1 Therefore, optimising disease control at time of conception and during pregnancy is in the best interest of mother and baby. 2, 3 Clinical practice guidelines for the management of IBD in pregnant women recommend ongoing anti-TNF therapy to maintain clinical remission in keeping with recommendations for UC and CD treatment in the nonpregnant state. 2, 4, 5 However, women often decrease the dose or stop prescribed medications without discussion with their physicians before or during pregnancy. 6, 7 Infliximab and adalimumab are IgG1 monoclonal antibodies directed at tumour necrosis factor (TNF)-alpha that cross the placenta efficiently in the second and third trimesters as a result of a specific FcRn receptor-mediated mechanism. 8 Consequently, infliximab and adalimumab concentrations may be up to fourfold higher in infant and cord blood as compared to the maternal peripheral blood. [9] [10] [11] While Julsgaard reported that infliximab clearance appeared slower than adalimumab clearance in exposed infants, the underlying mechanism was not identified. 12 Although intra-partum anti-TNF blockade does not appear to adversely affect the developing infant in the short term, infant drug levels are inversely related to the duration between the last intrapartum dose of anti-TNF therapy and time of birth. [12] [13] [14] [15] [16] Studies have investigated the rate of relapse in those who choose earlier intra-partum cessation of therapy in an attempt to minimise circulating levels of the drug in the exposed infant with mixed results. de Lima and colleagues reported no difference in relapse rates in women with sustained remission who stopped anti-TNF therapy before week 25 compared with the remainder of the group who continued therapy beyond week 30 (9.8% vs. 15.6%, P = 0.14). 17 In contrast, the GETAID group documented that discontinuation of anti-TNF therapy before week 30 led to a disease relapse in the intra-(14%) or early post-partum (32%) period. 18 Therefore, the putative benefit of lower infant anti-TNF drug levels must be balanced with the risks of an intra-or post-partum disease flare. Furthermore, the consequences of treatment hiatus which may result in decreased long-term treatment efficacy need to be considered. 19 While drug concentrations at time of birth in the mother, cord blood and infant have been well documented, anti-TNF drug levels through pregnancy have never been measured and it is not known how pregnancy influences the pharmacokinetics of anti-TNF agents. Therefore, the aim of this study was to assess serial anti-TNF drug levels in a prospective cohort of pregnant women with IBD on stable maintenance therapy with either infliximab or adalimumab.
METHODS
The University of Calgary IBD pregnancy clinic cares for women with a confirmed diagnosis of IBD who are contemplating pregnancy or are pregnant, providing pre-conception counselling and clinical follow-up each trimester and up to 6 months post-partum. The goal is to optimise disease control resulting in improved outcomes for both mother and baby. 2, 3, 20 A research registry is attached to the clinic and individuals who provide written informed consent undertake standardised questionnaires and serial serum bio-banking. The study was approved by the Conjoint Health Research Ethics Board at the University of Calgary (Ethics ID: 23830, Maternofetal outcomes in IBD).
Patients attending the IBD pregnancy clinic who were treated with an anti-TNF agent (infliximab or adalimumab) from August 2012 to September 2014 were prospectively enrolled if they became pregnant in the study period. If a woman gave birth more than once during the study period (n = 1), both pregnancies were included. There were five observational periods; pre-conception, trimester one, trimester two, trimester three and post-partum. However, it was possible, for a patient to receive two infusions in a single trimester resulting in some individuals providing six samples. At each visit, data on disease activity [Harvey-Bradshaw index (HBI) for CD patients, Simple Clinical Colitis Activity Index (SCCAI) for UC patients], medication use (including anti-TNF initiation date, dates of the intra-partum infusions or injections, concomitant thiopurine use) and pregnancy outcomes (including pre-term birth which was defined as delivery at gestational age of <37 weeks) were recorded on standardised questionnaires.
All data were reviewed by two treating physicians at the University of Calgary IBD pregnancy clinic (CS and YL). Individuals had serial serum bio-banking performed at time of recruitment (pre-conception or during pregnancy), at each subsequent trimester and post-partum. For patients recruited pre-conception, only sera collected within the 1 year prior to conception were analysed. All patients were on stable maintenance therapy and had completed standard induction dosing prior to enrolment.
All patients on infliximab were treated with~5 mg/kg based on a q6-8w schedule based on the pre-pregnancy weight and dosing interval. It is standard practice at this institution to provide dosing of infliximab rounded to the 100 mg vial and to maintain the same dose despite the expected intra-partum pregnancy weight gain (i.e. no dose escalation occurred during pregnancy). All patients on adalimumab received a standard 40 mg subcutaneous injection either bi-weekly or weekly, at the discretion of the treating physician. There were no changes in concomitant immunomodulator therapy or in infliximab or adalimumab dose or dosing intervals between the initial pre-pregnancy sample collection and subsequent samples collected during the pregnancy. Serum samples were obtained in the week preceding infliximab infusion (trough concentrations) and obtained at steady state for those on adalimumab. 21 The samples were collected in clot tubes, spun and the resultant sera aliquots were frozen at À80°C. At the conclusion of the study, the batched samples were sent to Prometheus Laboratories Inc., San Diego, CA, USA and serum drug levels (in lg/ mL) and anti-drug antibody levels (in U/mL) were measured using the validated homogenous mobility shift assays (ANSER infliximab and ANSER adalimumab). 22, 23 Infliximab was documented to be present if >1.0 lg/mL, and antibodies to infliximab present if >3.1 U/mL. The adalimumab threshold was >1.6 lg/mL for the presence of drug and >1.7 U/mL for the detection of adalimumab antibodies. Anti-drug antibodies could be detected in the presence of drug. Treating physicians were blinded to the drug levels (with samples being processed at the completion of the study period) to ensure that any dose or dosing schedule changes were not based on the drug level results. Descriptive statistics were analysed using the Wilcoxon rank sum test to compare medians. The Spearman correlation test was performed to assess the relationship between drug levels and time of last dose. The change over time (by trimester) in infliximab and adalimumab levels (primary outcomes of interest), albumin, BMI and CRP were analysed longitudinally during pregnancy using univariate linear modelling. Next, the change in infliximab and adalimumab drug levels across trimesters were adjusted for the clinical covariates of albumin, BMI and CRP using two distinct multivariate linear mixedeffects model (one for each drug). Linear mixed-effect models are extensions of linear regression models, and this modelling approach takes into account correlations between repeated measures on the same individual and allows for incomplete outcome data with the assumption that the missing data were random in nature. 24 The resulting b-estimate represents the change in drug level for a unit increase in that predictor. The MIXED procedure in SAS [Version 9.4, SAS system for Windows (SAS Institute, Cary NC, USA)] was used. A P-value of <0.05 was considered statistically significant.
RESULTS
Twenty-five women with IBD treated with anti-TNF therapy during pregnancy were recruited. There were 15 women treated with infliximab (8 CD, 7 UC) with a resultant 15 pregnancies. Ten women were treated with adalimumab intra-partum (nine CD, one UC) with a resultant 11 pregnancies. The median number of observations per individual was three (range 2-6). The background demographics of the women are shown in Table 1 . There were no significant differences between the infliximab and adalimumab treated groups with respect to age at last menstrual period, age at diagnosis, disease duration, anti-TNF therapy duration or gestational age at delivery ( 
Adalimumab cohort
The median adalimumab dose was 40 mg and was provided bi-weekly in nine of the 11 patients, and weekly in 2 patients at time of recruitment. While one patient was empirically dose escalated from bi-weekly to weekly adalimumab in her third trimester in response to active disease, it was subsequently determined that high level anti-adalimumab antibodies were present throughout the pregnancy in the absence of circulating drug, therefore the change in dose did not alter the analysis. The blood draw was performed at steady state and the median time between the blood draw and the subsequent injection was 4.0 days (IQR: 1.0-9.0 days). There was no correlation between adalimumab concentrations and the time since last dose (r = 0.16; P = 0.36). Two of 11 patients (18.2%) had antibodies to adalimumab with a median level of 19.5 U/mL (range 4.3-82.6 U/mL).
Pharmacokinetic data for infliximab and adalimumab
During the intra-partum period, albumin levels decreased (P < 0.05), BMI increased (P < 0.05) and CRP was stable (P > 0.05) for the infliximab and adalimumab cohorts irrespective of disease phenotype. The association between infliximab/adalimumab drug levels and albumin, BMI and CRP was assessed using linear regression. There was an inverse relationship between infliximab levels and CRP in CD (P = 0.03) but not in UC patients (P = 0.17). All other associations were not statistically significant (P > 0.05 for infliximabalbumin; infliximab-BMI; adalimumab-CRP; adalimumab-albumin; adalimumab-BMI). Figure 1 shows the individual patient data for infliximab while figure 2 shows the aggregate data of the median concentrations of the infliximab per trimester. On multivariate mixed modelling, only gestational age had a significant effect on infliximab levels during pregnancy (P = 0.02), after accounting for changes in albumin, BMI and CRP. (Table 2 ) The infliximab drug levels increased by 4.82 lg/mL per trimester in patients with CD (P < 0.01) and increased by 4.19 lg/mL per trimester in patients with UC (P < 0.01). (Figure 3 ) Figure 4 shows the individual patient data for adalimumab while figure 5 shows aggregate data of the median concentrations of adalimumab per trimester. Table 3 demonstrates there were no significant changes in adalimumab levels in pregnant women with IBD after accounting for albumin, BMI and CRP (increase of 0.54 lg/mL, P > 0.05). This was relevant for those with CD (P > 0.05) but there were insufficient data to analyse the effect of albumin, BMI and CRP on drug levels in UC (n = 1). monotherapy (5.28 lg/mL, IQR: 4.88-6.86 lg/mL; P = 0.73). At conception, 5 of 11 adalimumab patients were on concomitant azathioprine. One woman stopped the azathioprine in third trimester due to a rash. The median adalimumab concentration was higher in those on concomitant therapy vs. those without azathioprine (16.01 lg/mL, IQR: 11.04-17.02 lg/mL vs. 6.8 lg/mL, IQR: 0.0-14.4 lg/mL; P = 0.03).
Effect of concomitant immunosuppression

Effect of disease activity
Only one patient with UC treated with infliximab had an intra-partum flare. This occurred at week 35 with an SCCAI score of 5 and confirmatory physician global assessment despite a supra-therapeutic infliximab level of 28.0 lg/mL. A single patient with CD had active disease throughout all three trimesters, with HBI scores ranging from 9 to 14, with a confirmatory physician global assessment. She was subsequently discovered to have undetectable adalimumab drug levels with high-level antibodies (ranging from 18.42 to 71.98 U/mL) throughout pregnancy.
Effect on pregnancy outcomes
In the infliximab group, there were 13 terms births and 2 pre-terms births (at 34.6 and 36.2 weeks gestation respectively). Both mothers of the pre-term infants had inactive disease with HBI scores of 0 throughout the pregnancy. In the adalimumab group, there were nine term births and one pre-term birth (at 36 weeks gestation) in a patient with an intra-partum HBI score of 1.
One patient in the adalimumab group miscarried at 9 weeks gestation in the presence of therapeutic drug levels at week 7 (15.60 lg/mL) on adalimumab 40 mg bi-weekly dosing with a CRP of 1 lg/mL and an HBI score of 0.
DISCUSSION
Current guidelines support the notion that maintenance of remission is the most important factor in a successful pregnancy and that treatment with anti-TNF therapy does not result in adverse materno-fetal outcomes. 2 While it has been demonstrated that infliximab and adalimumab concentrations are higher in infant and cord blood as compared to the maternal peripheral blood, the preceding events concerning the intra-partum handling of anti-TNF agents have not previously been described. [9] [10] [11] Our study demonstrates the novel finding that infliximab levels increase significantly during the pregnancy even when the dose is not adjusted for resultant pregnancy weight gain, while adalimumab levels appeared stable with the use of a fixed (nonweight-based) dosing schedule. While albumin levels decreased significantly and BMI increased significantly during pregnancy, neither had a significant effect on infliximab or adalimumab levels during pregnancy in women with CD or UC. Infliximab levels appear to return to the pre/early pregnancy levels without changes to the dosing schedule post-partum.
There is efficient and active transplacental transfer of IgG molecules across the placenta in the second and third trimesters via the FcRn receptor system. umbilical cord/baby and in the mother's peripheral blood at the time of birth, the demonstration of higher ratios of infant to mother drug concentrations and persistence of anti-TNF drug levels in the exposed infant have been well documented. 9, 10, 12 Mahadevan reported that infliximab levels in infants exceeded maternal levels up to threefold and that these infants took up to 7 months to clear the drug. 9 Julsgaard et al. recently reported the median ratio of infant:mother drug concentration at birth was 1.97 for infliximab (95% CI, 1.50-2.43) and 1.21 for adalimumab (95% CI, 0.94-1.49). Furthermore, the mean time to drug clearance in infants was 7.3 months for infliximab (95% CI, 6.2-8.3) vs. 4.0 months for adalimumab (95% CI, 2.9-6.5; P < 0.0001). 12 Reassuringly, Mahadevan reported that the risk of increased infant infections at 12 months of age occurred only in those treated with anti-TNF with a thiopurine relative to those on anti-TNF therapy alone (RR: 1.50; 95% CI, 1.08-2.09). 27 Similarly, the majority of infants who developed infections in the Julsgaard study had also been exposed to combination therapy. 12 Children exposed to anti-TNF agents in utero appear to mount an adequate response to nonlive vaccines. 10, 11, 28 However, a fatal case of disseminated BCG infection highlights the risk of live vaccination in the presence of detectable anti-TNF concentrations. 29 Therefore, an understanding of intra-partum pharmacokinetics may improve clinical care in both mother and baby. Thus far, an explanation for the differential intra-and post-partum clearance of infliximab and adalimumab has not been provided. Pharmacokinetic factors including absorption, distribution, metabolism and elimination are altered during pregnancy. Infliximab is administered parenterally, with a rapid absorption and 100% bioavailability. Adalimumab is administered subcutaneously, with bioavailability ranging from 50% to 100%. Extracellular degradation resulting from proteolysis at the injection site, can be affected by a number of disease states including hypertension, diabetes and infection, however, there are no data on the effect of pregnancy on protease expression and activity. 30 Theoretically, pregnancyrelated vasodilation or alterations in the subcutaneous tissue may result in increased degradation at the injection site altering adalimumab absorption. 31 Anecdotally, it is common practice for women to change injection site from the abdominal wall to the thigh or gluteal region during pregnancy. Dissimilar fat compositions in different anatomical locations and adipose gain could conceivably play a role in the disparate serum drug levels during pregnancy. Route of administration may therefore play a role in the observed differences in infliximab and adalimumab intra-partum drug levels. Furthermore, rather than viewing the increase in infliximab levels as being the anomaly, perhaps changes in the absorption of adalimumab may mute the increase in adalimumab levels across trimesters, resulting in a relative 'stability' of adalimumab concentrations. Distribution, metabolism and elimination of the anti-TNF agents are less likely to contribute to the observed findings. During pregnancy, both body mass and plasma volume increase, however, monoclonal antibodies have a high molecular weight and hydrophilic profile resulting in a relatively small volume of distribution. Therefore, changes in total body water should not significantly alter the pharmacokinetics of monoclonal antibodies. 32 In keeping with this, our data demonstrate that there is no need to increase the dose of either anti-TNF agent in response to pregnancy weight gain. Anti-TNF clearance has been shown to be accelerated in the presence of acute disease, with associated hypoalbuminemia resulting in an increased clearance of infliximab. Furthermore, there is leakage through the extensively ulcerated intestinal mucosa, as demonstrated by high faecal concentrations of the drug. 33 However, hypoalbuminemia did not appear to influence infliximab or adalimumab clearance in our cohort. We propose that pregnancy induces a relative (dilutional) rather than an absolute hypoalbuminemia. Furthermore, the FcRn receptor protects IgG molecules from intra-cellular catabolism. 8 Lastly, it seems unlikely that the FcRn or elimination mechanisms would differentially handle one anti-TNF vs. the other given the similarities between the molecules. It is unclear if physiological changes associated with pregnancy alter monoclonal antibody dose requirements for maintenance of disease remission or if the relative immunosuppressant state of pregnancy may suppress anti-drug antibody formation during pregnancy. The supra-therapeutic infliximab levels may reflect a pregnancy-related phenomena given that drug concentrations appear to return to pre-pregnancy levels postpartum. We observed higher trough concentrations of infliximab in our cohort (median levels of 10.3 and 21.0 lg/mL in the second and third trimester respectively) than the recommended 3-7 lg/mL of optimised maintenance dosing studies such as TAXIT. 34 Therapeutic adalimumab levels were also maintained during pregnancy with a median level of 11.0 lg/mL. Concomitant immunosuppression with azathioprine led to significantly higher adalimumab but not infliximab levels despite data suggesting that combined immunosuppression increases drug concentrations. 35, 36 The higher intra-partum anti-TNF levels in our cohort may also reflect that women in our centre were strongly encouraged at the pre-conception visit to achieve both clinical and endoscopic remission and nearly all maintained deep remission throughout pregnancy. In a post hoc analysis of the Active Ulcerative Colitis Trial (ACT-1 and ACT-2), the median clearance of infliximab was significantly lower in responders than in nonresponders to infliximab. 37 Similarly, the TAXIT study observed higher median infliximab trough concentrations in patients exhibiting mucosal healing than those without mucosal healing [5.2 mg/mL (IQR: 3.9-7.7 mg/mL) vs. 2.8 mg/ mL (IQR: 1.5-6.0 mg/mL); P < 0.01]. 34 Ungar demonstrated this as a class effect with significantly higher infliximab and adalimumab levels (P = 0.0002 and P = 0.1 respectively) in individuals who achieved complete remission than those with active disease. 38 Julsgaard et al. reported that the mean infliximab half-life was 3.7 times longer and the adalimumab halflife was twofold longer in exposed infants than in nonpregnant adults. 12 We hypothesise that the infant's healthy gastrointestinal tract may act as a mediator of reduced drug clearance resulting in longer anti-TNF half-lives in exposed infants, in comparison to individuals with active disease who clear drug more quickly. Furthermore, high concentrations of FcRN in the neonate may contribute to drug salvage. In the TAXIT study, if patients exhibited supra-therapeutic levels, the dose was first reduced, then the interval between infusions was prolonged. Reassuringly, there was no significant change in the proportion maintaining clinical or biochemical remission in the short and long term with this dose de-escalation regimen. 34 A similar regimen incorporating therapeutic drug monitoring during pregnancy for individuals on anti-TNF agents could be considered with women who are in stable remission having drug levels targeted to the lower end of the therapeutic range in the pre-conception period with drug levels rechecked during the second trimester to guide third trimester dosing. It would be premature to provide recommendations on choice of anti-TNF agent or an optimal dosage regimen based on these data alone. There are obvious risks in electively changing anti-TNF agents immediately prior to or during pregnancy in the absence of an adverse effect or lack of response. The SWITCH study demonstrated elective switching from one anti-TNF to another was associated with loss of tolerance and loss of efficacy within 1 year. 39 Even in patients treated with concomitant therapy, withdrawal of the anti-TNF agent led to disease relapse in 50% of patients at 1 year (STORI trial). 40 Our study reiterates the recommendation that infants exposed to anti-TNF in utero should not receive live vaccines prior to 12 months of life, or anti-TNF drug levels should be confirmed to be non-existent if vaccines are being considered prior. Jurisdictions vary in their recommendations regarding vaccination, and parents, physicians and public health authorities should be made aware that the live rotavirus vaccine which is given as early as 6 weeks post-partum should be avoided, be aware of inactivated alternatives, (e.g. inactivated poliovirus vaccine rather than the oral live poliovirus vaccine), and should counsel patients regarding elective travel vaccinations accordingly.
Limitations of this study include the inability to report on drug levels in the mother at time of birth, umbilical cord or in the newly born infant, however, this has been documented well in other studies.
9, 10, 12 Therefore, we
were not able to comment on infant drug clearance. The sample size was limited, and the study would be strengthened with more subjects and a larger number of serial observations per individual. The authors acknowledge that the small sample size may have resulted in inadequate power to detect a change in adalimumab levels. Given the lack of robust data on adalimumab, it may be cautionary to perform therapeutic drug monitoring in the second trimester for adalimumab-treated women to inform third trimester dosing, similar to that recommended for mothers prescribed infliximab. The clearance of other anti-TNF monoclonal antibodies including golimumab and certolizumab are still unknown but data suggest that certolizumab levels in the infant are negligible due to decreased transplacental transfer resulting from the lack of the Fc portion, which is necessary for the binding to FcRn. 9 The study of intra-partum levels of other IgG1 molecules would also be of interest.
In conclusion, this prospective observational study demonstrates the novel finding that infliximab levels increase during pregnancy after accounting for BMI, albumin and CRP despite stable maintenance dosing based on pre-pregnancy weight. While we were unable to demonstrate a similar pattern with adalimumab use during pregnancy (perhaps as a consequence of the smaller cohort size), the data overall provide rationale for detectable levels in the mother at time of delivery, the presence of higher neonatal to maternal levels and may explain documented prolonged clearance in the infant. Based on these results, we suggest that anti-TNF drug levels may be targeted to the lower end of the therapeutic range in the pre-conception period in patients who are in stable remission, to be rechecked at the second trimester, and then a decision to provide a third trimester dose to be made accordingly, with resumption of scheduled dosing post-partum. Future studies should determine ways to model a gestational age at which the last intra-partum dose of anti-TNF therapy may result in sustained therapeutic levels for the mother, yet limiting infant drug exposure, with the goal of limiting missed live vaccinations in the infant, noting that local vaccination guidelines vary between jurisdictions.
AUTHORSHIP
Guarantor of the article: CHS. Authors' contributions: CHS contributed to the study design, data collection, data analysis, manuscript drafting and editing. YL, NVC and GGK contributed to the study design, data analysis and critical revision of the manuscript for important intellectual content. DT contributed to data analysis. EE and GB contributed to data collection. MJS, PB and SG contributed to the critical revision of the manuscript for important intellectual content. RP contributed to the study design and critical revision of the manuscript for important intellectual content. All authors have approved the final version of the manuscript, including the authorship list.
